First in Human Phase 1 Dose Escalation and Expansion Clinical Trial to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of Intravenous AROG4-01 in Patients with Advanced Solid Tumors.

2024-517569-18-00 Protocol AROG4-01-01 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 3 sites · Protocol AROG4-01-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 40
Countries 1
Sites 3

Patients with advanced refractory solid tumors.

Key facts

Sponsor
Applied Research Using Omic Sciences S.L.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2025-04-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-517569-18-00
ClinicalTrials.gov
NCT06652529

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with advanced refractory solid tumors.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Applied Research Using Omic Sciences S.L.

Sponsor organisation
Applied Research Using Omic Sciences S.L.
Address
Ex Victor Pradera, Calle De Can Roses 45 Calle De Can Roses 45
City
Cornella De Llobregat
Postcode
08940
Country
Spain

Scientific contact point

Organisation
Applied Research Using Omic Sciences S.L.
Contact name
Carme Plasencia

Public contact point

Organisation
Applied Research Using Omic Sciences S.L.
Contact name
Carme Plasencia

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruitment pending 40 3
Rest of world 0

Investigational sites

Spain

3 sites · Authorised, recruitment pending
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Institut Catala D'oncologia
Oncology, Carretera Canyet S/n, 08916, Badalona

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-01-15 Spain Acceptable
2025-04-11
2025-04-11
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-05-06 Spain Acceptable
2025-04-11
2025-05-06